Situation Analysis of Early Implementation of Programmatic Management of Tuberculosis Preventive Treatment among Household Contacts of Pulmonary TB Patients in Delhi, India
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Setting
2.2.1. General Setting
2.2.2. Specific Setting
2.3. Study Population
2.3.1. For the Quantitative Phase
2.3.2. For the Qualitative Phase
2.4. Data Variables and Data Collection
2.4.1. Quantitative Component
2.4.2. Qualitative Component
2.5. Data Entry and Analysis
2.6. Ethics
3. Results
3.1. Enablers
3.2. Barriers
3.3. Possible Solutions
4. Discussion
Strength and Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- WHO. Global Tuberculosis Report 2022; World Health Organization: Geneva, Switzerland, 2022; Available online: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 (accessed on 17 November 2022).
- CTD. India TB Report 2023, 3rd ed.; Dabbs, D.J., Ed.; Central TB Division, Ministry of Health and Family Welfare: New Delhi, India, 2023. Available online: https://tbcindia.gov.in/showfile.php?lid=3680 (accessed on 1 September 2023).
- Cohen, A.; Mathiasen, V.D.; Schön, T.; Wejse, C. The global prevalence of latent tuberculosis: A systematic review and meta-analysis. Eur. Respir. J. 2019, 54, 1900655. [Google Scholar] [CrossRef] [PubMed]
- ICMR. National Tuberculosis Prevalence Survey—2019–2021. Indian Council of Medical Research and National Institute for Research in Tuberculosis. 2021. Available online: https://tbcindia.gov.in/showfile.php?lid=3659 (accessed on 1 September 2023).
- Menzies, N.A.; Wolf, E.; Connors, D.; Bellerose, M.; Sbarra, A.N.; Cohen, T.; Hill, A.N.; Yaesoubi, R.; Galer, K.; White, P.J.; et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: A systematic review of the validity of modelling assumptions. Lancet Infect. Dis. 2018, 18, e228–e238. [Google Scholar] [CrossRef] [PubMed]
- Getahun, H.; Matteelli, A.; Chaisson, R.E.; Raviglione, M. Latent Mycobacterium tuberculosis infection. N. Engl. J. Med. 2015, 372, 2127–2135. [Google Scholar] [CrossRef] [PubMed]
- WHO End TB Strategy. Geneva. 2015. Available online: https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy (accessed on 1 September 2023).
- Zunza, M.; Gray, D.M.; Young, T.; Cotton, M.; Zar, H.J. Isoniazid for preventing tuberculosis in HIV-infected children. Cochrane Database Syst. Rev. 2017, 8, CD006418. [Google Scholar] [CrossRef] [PubMed]
- Akolo, C.; Adetifa, I.; Shepperd, S.; Volmink, J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst. Rev. 2010, 1, CD000171. [Google Scholar] [CrossRef] [PubMed]
- Golub, J.E.; Pronyk, P.; Mohapi, L.; Thsabangu, N.; Moshabela, M.; Struthers, H. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: A prospective cohort. AIDS 2009, 23, 631–636. [Google Scholar] [CrossRef] [PubMed]
- Badje, A.; Moh, R.; Gabillard, D.; Guéhi, C.; Kabran, M.; Ntakpé, J.-B. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: Long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob. Health 2017, 5, 1080–1089. [Google Scholar] [CrossRef]
- Surie, D.; Interrante, J.D.; Pathmanathan, I.; Patel, M.R.; Anyalechi, G.; Cavanaugh, J.S.; Kirking, H.L. Policies, practices and barriers to implementing tuberculosis preventive treatment-35 countries, 2017. Int. J. Tuberc. Lung Dis. 2019, 23, 1308–1313. [Google Scholar] [CrossRef]
- NTEP Guidelines for Programmatic Management of TB Preventive Treatment in India. National Tuberculosis Elimination Program Ministry of Health and Family Welfare. New Delhi. 2021. Available online: https://tbcindia.gov.in/showfile.php?lid=3625 (accessed on 1 September 2023).
- WHO. WHO consolidated guidelines on tuberculosis. Module 1: Prevention—Tuberculosis preventive treatment. N. Engl. J. Med. 2020. Available online: https://iris.who.int/bitstream/handle/10665/331170/9789240001503-eng.pdf (accessed on 1 September 2023).
- Otero, L.; Battaglioli, T.; Ríos, J.; De la Torre, Z.; Trocones, N.; Ordoñez, C.; Seas, C.; Van der Stuyft, P. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: An analysis of routine data. Trop. Med. Int. Health 2020, 25, 346–356. [Google Scholar] [CrossRef]
- Rekha, B.; Jagarajamma, K.; Chandrasekaran, V. Improving screening and chemoprophylaxis among child contacts in India’s RNTCP: A pilot study. Int. J. Tuberc. Lung Dis. 2013, 17, 163–168. [Google Scholar] [CrossRef] [PubMed]
- Rekha, V.V.B.; Jagarajamma, K.; Wares, F.; Chandrasekaran, V.; Swaminathan, S. Contact screening and chemoprophylaxis in India’s Revised Tuberculosis Control Programme: A situational analysis. Int. J. Tuberc. Lung Dis. 2009, 13, 1507–1512. [Google Scholar]
- Pothukuchi, M.; Nagaraja, S.B.; Kelamane, S. Tuberculosis contact screening and isoniazid preventive therapy in a South Indian district: Operational issues for programmatic consideration. PLoS ONE 2011, 6, e22500. [Google Scholar] [CrossRef] [PubMed]
- Shivaramakrishna, H.R.; Frederick, A.; Shazia, A. Isoniazid preventive treatment in children in two districts of South India: Does practice follow policy? Int. J. Tuberc. Lung Dis. 2014, 18, 919–924. [Google Scholar] [CrossRef]
- Singh, A.R.; Kharate, A.; Bhat, P.; Kokane, A.M.; Bali, S.; Sahu, S.; Verma, M.; Nagar, M.; Kumar, A.M.V. Isoniazid preventive therapy among children living with tuberculosis patients: Is it working? A mixed-method study from Bhopal, India. J. Trop. Pediatr. 2017, 63, 274–285. [Google Scholar] [CrossRef]
- Makova, N.C.; Muchekeza, M.; Chirenda, J.; Chadambuka, A.; Govha, E.; Juru, T.P.; Gombe, N.T.; Tshimanga, M. An evaluation of the isoniazid preventive therapy program performance for under-fives in Kwekwe City, January 2019-December 2020: A descriptive cross-sectional study. Pan Afr. Med. J. 2022, 42, 104. [Google Scholar] [CrossRef]
- Ryckman, T.; Weiser, J.; Gombe, M.; Turner, K.; Soni, P.; Tarlton, D.; Mazhidova, N.; Churchyard, G.; Chaisson, R.E.; Dowdy, D.W. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: A modelling analysis. Lancet Glob. Health 2023, 11, e1205–e1216. [Google Scholar] [CrossRef]
- Government of India O of the Registrar General and Census Commissioner. Census of India 2011. 2011. Available online: https://censusindia.gov.in/census.website/data/HH2011 (accessed on 18 November 2022).
- WHO. Service Availability and Readiness Assessment (SARA); World Health Organization: Geneva, Switzerland, 2015; Available online: https://www.who.int/data/data-collection-tools/service-availability-and-readiness-assessment-(sara) (accessed on 1 September 2023).
- Tong, A.; Sainsbury, P.; Craig, J. Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. International J. Qual. Health Care 2007, 19, 349–357. [Google Scholar] [CrossRef]
- CTD. Operational Manual for Partnerships under National Tb Elimination Programme; Central TB Division, Ministry of Health & Family Welfare: New Delhi, India, 2023; Available online: https://tbcindia.nic.in/showfile.php?lid=3705 (accessed on 1 September 2023).
- Campbell, J.I.; Menzies, D. Testing and Scaling Interventions to Improve the Tuberculosis Infection Care Cascade. J. Pediatr. Infect. Dis. Soc. 2022, 11, S94–S100. [Google Scholar] [CrossRef]
- Kadyrov, M.; Thekkur, P.; Geliukh, E.; Sargsyan, A.; Goncharova, O.; Kulzhabaeva, A.; Kadyrov, A.; Khogali, M.; Harries, A.D.; Kadyrov, A. Contact Tracing and Tuberculosis Preventive Therapy for Household Child Contacts of Pulmonary Tuberculosis Patients in the Kyrgyz Republic: How Well Are We Doing? Trop. Med. Infect. Dis. 2023, 8, 332. [Google Scholar] [CrossRef]
- Fentahun, N.; Wasihun, Y.; Mamo, A.; Gebretsadik, L.A. Contact Screening and Isoniazid Preventive Therapy Initiation for Under-Five Children among Pulmonary Tuberculosis-Positive Patients in Bahir Dar Special Zone, Northwest Ethiopia: A Cross-Sectional Study. Tuberc. Res. Treat. 2020, 2020, 6734675. [Google Scholar] [CrossRef] [PubMed]
- van Wyk, S.S.; Reid, A.J.; Mandalakas, A.M.; A Enarson, D.; Beyers, N.; Morrison, J.; Hesseling, A.C. Operational challenges in managing Isoniazid preventive therapy in child contacts: A high-burden setting perspective. BMC Public Health 2011, 11, 544. [Google Scholar] [CrossRef] [PubMed]
- Egere, U.; Sillah, A.; Togun, T.; Kandeh, S.; Cole, F.; Jallow, A.; Able-Thomas, A.; Hoelscher, M.; Heinrich, N.; Hill, P.C.; et al. Isoniazid preventive treatment among child contacts of adults with smear-positive tuberculosis in The Gambia. Public Health Action 2016, 6, 226–231. [Google Scholar] [CrossRef] [PubMed]
- Samandari, T.; Agizew, T.B.; Nyirenda, S.; Tedla, Z.; Sibanda, T.; Shang, N.; Mosimaneotsile, D.; Motsamai, O.I.; Bozeman, L.; Davis, N.K.; et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: A randomised, double-blind, placebo-controlled trial. Lancet 2011, 377, 1588–1598. [Google Scholar] [CrossRef]
- PIB Hon’ble Prime Minister Inaugurates the One World TB Summit 2023 in Varanasi. New Delhi. 2023. Available online: https://pib.gov.in/PressReleaseIframePage.aspx?PRID=1910318#:~:text=He%20pointed%20to%20Indian%20innovations,of%20one%20drug%20every%20day (accessed on 1 September 2023).
- Matteelli, A.; Lovatti, S.; Sforza, A.; Rossi, L. Programmatic management of tuberculosis preventive therapy: Past, present, future. Int. J. Infect. Dis. 2023, 130, S43–S46. [Google Scholar] [CrossRef]
- Barss, L.; Obeng, J.; Fregonese, F.; Oxlade, O.; Adomako, B.; Afriyie, A.O.; Frimpong, E.D.; Winters, N.; Valiquette, C.; Menzies, D. Solutions to improve the latent tuberculosis Cascade of Care in Ghana: A longitudinal impact assessment. BMC Infect. Dis. 2020, 20, 352. [Google Scholar] [CrossRef]
District 1 | District 2 | District 3 | Comments | |||
TPT Implementation | Project Mode | Govt ‘Treat Only’ | Govt ‘Test and Treat’ | |||
Data source | NIKSHAY | Project data | NIKSHAY | NIKSHAY |
| |
Contact Tracing | Index patients | 1860 | 2150 @ | 1062 | 933 |
|
Initial home visit/assessment completed | 1811/1860 (97.4%) | 1563/2150 (72.7%) | 507/1062 (47.7%) | 640/933 (68.6%) | ||
Index with at least 1 HHC enlisted | 1738 (96.0%) | 1249 (79.9%) | 488 (45.9%) | 578 (62.0%) | ||
Total HHC enlisted (Avg. HH size:) | 7515 (5.1) | 4162 (3.7) | 1712 (2.6) | 1922 (3.1) | ||
Screening | 4s Screening completed | 6373/7515 (84.8%) | 4042/4162 (97.1%) | 1582/1712 (92.4%) | 1817/1922 (94.5%) |
|
HHC with TB Symptom | 346/6373 (5.4%) | 55/4042 (1.4%) | 32/1582 (2.0%) | 51/1817 (2.8%) | ||
Evaluation for TB | Evaluated for TB | 166/346 (48.0%) | 2323 $ | 9/32 (28.1%) | 18/51 (35.3%) |
|
HHC Diagnosed TB out of those who were evaluated | 100/166 (60.2%) | Not recorded | 6/9 (66.7%) | 10/18 (55.6) | ||
Initiated on TB treatment | 64/100 (64.0%) | Not recorded | 6/6 (100%) | 8/10 (80.0%) | ||
TPT initiation | Eligible for TPT * | 1163/6273 ^ (18.5%) | 3863/4042 ^ (95.6%) | 1094/1576 ^ (69.4%) | 1189/1807 (65.8%) |
|
Provided TPT among those who were eligible * | 1054/1163 (90.6%) | 2274/3863 (58.9%) | 1081/1094 (98.8%) | 1162/1189 (97.8%) | ||
Provided TPT among those who should eligible ^ | 1054/6273 (16.8%) | - | 1081/1576 (68.6%) | - | ||
TPT completion | Completed TPT | Cannot be assessed | 2114/2274 (93.0%) | Cannot be assessed | Cannot be assessed |
|
Domain | Activity | Status * | Comments/Notes |
---|---|---|---|
Organization Structure | State TPT committee | Established | Need to establish more regular meetings |
TPT implementation plan in annual PIP | Integrated | ||
Budget for TPT allocated | Allocated | No separate budget | |
Implemented early at all the center | Completed | PPM be utilized at low-performing/high-load center | |
Mapping activity, beneficiary, training, drugs and logistics | Completed | Regular mapping needed | |
Advocacy plan | Prepared | More active and coverage required | |
Mechanism for TBI screening established | Partially established | ‘Treat only’ strategy is present in two district while ‘Test and Treat’ in third. ‘Test and Treat’ strategy can be utilized | |
Active case finding integrating | Completed | Active case finding supplements | |
TPT implemented at private settings | Not completed | ||
Human Resource (HR) and Training | DOT provider/treatment supporter engagement in TPT | Completed | DOT provider is focal person |
HR mapping | Partially Completed | In Project mode district, NGO is supplementing DOT provider. In public mode districts, additional staffing required. May create new care dedicated to TPT | |
Induction training | Completed | All the concern staff are trained | |
Periodic training | Irregular | Frequent training required, special training for data manager | |
Linkage in HMS (Nikshay portal) | Not linked | Contact tracing and TPT register data on NIKSHAY do not comprehend each other Not updated regular basis Improve data updating and alignment | |
Mechanism for Review data established | Not linked to HMS | Data is reviewed manually, not embedded in NIKSHAY Deficiency in monitoring, data management, and supportive supervision. Training and support needed | |
Community Engagement | Community volunteers identified and trained | Completed | TB survivors and champions trained |
Advocacy in community | Partially completed | Limited to mass media and IEC activity Sandwiched with other IEC Increase coverage and prioritization required | |
Diagnostics | TBI tests | Partially available | TST available in one district, IGRA not utilized in any center. No provision for outsourcing; explore possibilities |
X-ray | Utilized | In Project mode district, free Xray of all adult cases at close to people home, while in government-run district, only at government health center | |
Drugs and Logistics | Drugs supply and mapping | Initial phase | Improve supply chain Local purchase not sustainable Separate individual beneficiary box with drug for entire duration |
Space for drug storage | Identified and upgraded | ||
6H and 3HP drugs | Added in program | Availability is not regular | |
TPT adherence mechanisms | Partially established | Adherence by telephonic or pill counts, not home visit, expand mechanisms | |
ADR management | Established | ||
Logistics for recording and reporting | Adequate | Not in use to expected level | |
Private Provider Engagement | Private provider engagement | Partial | Limited to one center, expand coverage |
Supports for various activities ^ | Partially completed | No provision for drug dispensing, TBI screening (IGRA, C-Tb) Expand services |
Themes | Categories | Verbatim Quotes |
---|---|---|
barrier to TPT | Not disease | “No matter how much you counsel and make them understand, they say that they are not sick, so why should they be taking medicines for 6 months?”—Senior Treatment Supervisor (STS), 45 y, Male (M) with >5 years (y) experiences. |
Drug supply/procurement | “only the drugs are not in supply. We can do local purchasing, but we don’t have enough funding to purchase drugs for all the beneficiaries.”—District TB officer (DTO), 40+ y, M, with >10 y experiences). | |
Data management/training | “…there was hindrance that the initial cascade training of the staff was not that effective……resulted in big issue of correct data entry. We then retrained these staffs in data entry and we observe improvement but again this is still prevailing.”—State Level TB officer), 50+ y, M, with >20 y experiences. | |
Drug resistance | “they also think that if they take drug now, and in future if they develop disease, they might have resistance to the drugs. this is some concern especially among educated population.”—DTO, 40+ y, M, with >15 y experiences. | |
Private provider | “Convincing them to have treatment for TPT is a challenge especially who are well read and in an era of easy access to Google any other information… there is a reluctance among physicians especially private physicians…”—State-level TB officer, 50+ y, M, with >20 y experiences. | |
Long duration of treatment | “…there is a sense (among household contacts) that they do not had any disease, so why should take medicine that too for 6 months, it is a long term.”—Project staff, 30 y, F, with 5 y experiences. | |
High patient load/overburden | “we need manpower, because we have only one tbhv (Health Visitor), which is being used for distribution of drugs and ration food packs, for active contact tracing, bank detail DBT (direct bank transfer), and TPT implementation. so work load is high.” DTO, 40+ y, M, with >10 y experiences). | |
Side effects | “lost to follow up has also been there who have had adverse reactions. Many said they were nervous, itchy, feeling restless, they did not complete (TPT).”—Project staff, 30 y, F, with 5 y experiences. | |
Possible solutions to TPT | Counselling | “It mainly depends on our counselling. As we explain it to them that currently, there is only one patient in the family and in future the other members are too vulnerable for the same. We find that patients come to take the medicine and generally get agree to it.”—State-level TB officer, 50+ y, M, with >20 y experiences. |
Staff recruitment | “we required new staff”—DTO, 40+ y, M, with >10 y experiences. | |
Streamlining contact tracing | “As when the patient visits the center, the details of their household contacts are taken. Then it is conveyed to the patient that the health volunteer will have meeting to the contacts.”—DTO, 50+ y, M, with >20 y experiences). | |
Weekly regimen/shorter regimen | “3HP is good as its course is for (only) three months and patients do not have to suffer or take medication for longer time. Its good also because one has to take medicine only once a week.”—Project staff, 48 y, F, with >10 y experiences. | |
Awareness/stigma reduction | “(among awareness programs) we should focus on the community level that everyone should be aware about this disease and there should be no stigma related to this.”—Project staff, 35 y, M with 3 y experiences. | |
Local purchasing | “there was shortage many times but it’s not a costly drug so we do local purchasing and provide to the patients.”—Medical officer, 45 y+, M with 15 y+ experiences). |
Challenge | Solutions |
---|---|
Drugs unavailability, erratic drug supply, procurement challenges | Central procurement of drugs Ensure timely availability of drugs Local purchasing with dedicated budget |
Apprehension about initiating TPT Adherence and lost to follow-up Side effects | Educate and raise awareness about TPT Enhanced communication strategies Improved monitoring and home visits Technology-driven communication Utilizing CHW (ASHA) Evidence generation |
Limited availability of TBI diagnostics | Capacity building PPSA and PPM |
Long duration amd daily treatment INH resistance with monotherapy (6H) | Consider other drugs with shorter duration (3HP) |
Overburdened human resources (HR) Data entry and system issues TPT data on HIMS (NIKSHAY) not available/unreliable | Dedicated HR for TPT Private sector involvement Regular supportive supervision Weekly and fortnightly Monitoring |
Not in private sector, private provider reluctance utility of TPT | Utilize PPM provisions Evidence generation |
Stigma associated with TB | Strengthened community engagement TB champions |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alvi, Y.; Philip, S.; Anand, T.; Chinnakali, P.; Islam, F.; Singla, N.; Thekkur, P.; Khanna, A.; Vashishat, B. Situation Analysis of Early Implementation of Programmatic Management of Tuberculosis Preventive Treatment among Household Contacts of Pulmonary TB Patients in Delhi, India. Trop. Med. Infect. Dis. 2024, 9, 24. https://doi.org/10.3390/tropicalmed9010024
Alvi Y, Philip S, Anand T, Chinnakali P, Islam F, Singla N, Thekkur P, Khanna A, Vashishat B. Situation Analysis of Early Implementation of Programmatic Management of Tuberculosis Preventive Treatment among Household Contacts of Pulmonary TB Patients in Delhi, India. Tropical Medicine and Infectious Disease. 2024; 9(1):24. https://doi.org/10.3390/tropicalmed9010024
Chicago/Turabian StyleAlvi, Yasir, Sairu Philip, Tanu Anand, Palanivel Chinnakali, Farzana Islam, Neeta Singla, Pruthu Thekkur, Ashwani Khanna, and BK Vashishat. 2024. "Situation Analysis of Early Implementation of Programmatic Management of Tuberculosis Preventive Treatment among Household Contacts of Pulmonary TB Patients in Delhi, India" Tropical Medicine and Infectious Disease 9, no. 1: 24. https://doi.org/10.3390/tropicalmed9010024
APA StyleAlvi, Y., Philip, S., Anand, T., Chinnakali, P., Islam, F., Singla, N., Thekkur, P., Khanna, A., & Vashishat, B. (2024). Situation Analysis of Early Implementation of Programmatic Management of Tuberculosis Preventive Treatment among Household Contacts of Pulmonary TB Patients in Delhi, India. Tropical Medicine and Infectious Disease, 9(1), 24. https://doi.org/10.3390/tropicalmed9010024